Free tool
FAERS Monitor: Cortisone Acetate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009458 or its brand name (Cortisone Acetate, Cortisone Acetate). Reports on generic versions are filed under their own applications.
Reports
12,501
Serious
11,946
96% of reports
Hospitalization
5,368
Death reported
3,917
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- systemic lupus erythematosus6,357
- pain6,279
- pemphigus6,238
- drug ineffective6,195
- alopecia6,123
- rheumatoid arthritis6,108
- abdominal discomfort6,037
- fatigue5,760
- glossodynia5,630
- swelling5,488
- hand deformity5,218
- wound5,067
- rash5,027
- arthropathy4,867
- contraindicated product administered4,607
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 38 |
| 2006 | 110 |
| 2007 | 152 |
| 2008 | 40 |
| 2009 | 20 |
| 2010 | 69 |
| 2011 | 371 |
| 2012 | 598 |
| 2013 | 25 |
| 2014 | 36 |
| 2015 | 92 |
| 2016 | 230 |
| 2017 | 180 |
| 2018 | 233 |
| 2019 | 364 |
| 2020 | 735 |
| 2021 | 2,091 |
| 2022 | 1,649 |
| 2023 | 949 |
| 2024 | 2,102 |
| 2025 | 1,759 |
| 2026 | 642 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,658 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 6,238 | 1673.0 | 1623.0 | 5,229,967 |
| hand deformitySignal | 5,218 | 1110.1 | 1077.0 | 3,485,647 |
| glossodyniaSignal | 5,630 | 564.8 | 551.1 | 2,374,624 |
| woundSignal | 5,067 | 372.2 | 363.1 | 1,538,012 |
| systemic lupus erythematosusSignal | 6,357 | 366.8 | 359.3 | 1,906,998 |
| contraindicated product administeredSignal | 4,607 | 301.7 | 294.0 | 1,172,362 |
| arthropathySignal | 4,867 | 161.3 | 157.6 | 709,399 |
| swellingSignal | 5,488 | 104.7 | 102.6 | 533,122 |
| rheumatoid arthritisSignal | 6,108 | 95.6 | 93.8 | 543,912 |
| abdominal discomfortSignal | 6,037 | 62.8 | 61.6 | 356,561 |
| alopeciaSignal | 6,123 | 54.1 | 53.1 | 312,119 |
| rashSignal | 5,027 | 19.6 | 19.2 | 89,637 |
| painSignal | 6,279 | 17.4 | 17.1 | 98,718 |
| fatigueSignal | 5,760 | 12.5 | 12.3 | 62,998 |
| drug ineffectiveSignal | 6,195 | 7.9 | 7.8 | 39,904 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.